Clinical trial · no report yet · Phase 3
NCT05184712
Phase 3 Clinical Study of AK112 for NSCLC Patients
- NCT05184712 ↗
- Active, not recruiting
- Akeso
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Bluesky threads | 6 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Double-blind, Multi-center, Phase III Study of AK112 Combined With Pemetrexed and Carboplatin Versus Placebo Combined With Pemetrexed and Carboplatin in Patients With Locally Advanced or Metastatic EGFR-mutant Non-squamous NSCLC Who Have Failed Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKIs)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Non-Squamous Non-small Cell Lung Cancer
- Interventions
- Ivonescimab (SMT112 or AK112) Injection; Placebo Injection
- Arms
- Ivonescimab (SMT112 or AK112) in combination with Pemetrexed and Carboplatin · Experimental
- Placebo in combination with Pemetrexed and Carboplatin · Placebo comparator
- Enrollment
- 322
- Primary outcomes
- Progression-free survival (PFS)
- Sponsor
- Akeso
- Start
- Jan 25, 2022
- Primary completion
- Mar 10, 2023
- Results posted
- No
- Registry record
- NCT05184712 · updated Mar 4, 2026
Publications
linked from the registry- HARMONi-A Study Investigators; Fang W, Zhao Y, Luo Y, Yang R, Huang Y, He Z, Zhao H, Li M, Li K, Song Q, Du X, Sun Y, Li W, Sun L, Wang Z, Yang K, Fan Y, Liu B, Zhao H, Hu Y, Jia L, Xu S, Yi T, Lv D, Lan H, Li M, Liang W, Wang Y, Yang H, Jia Y, Chen Y, Lu J, Shi M, Liu C, Zhou M, Zhou J, Liu X, Zhou N, He M, Dong X, Chen H, Chen Y, Su H, Li X, Zhang Z, Yang L, Liu Y, Chen L, Hou X, Zhang Y, Guo J, Ma R, Lu H, Wu D, Feng W, Li W, Huang J, Wang Y, Song X, Peng J, Liu L, Guo Y, Li W, Xia M, Lu D, Hu M, Wang ZM, Li B, Xia MY, Zhang L. Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial. JAMA. 2026 Jul 28;336(4):306-314. doi: 10.1001/jama.2026.7745. PubMed 42307937
- HARMONi-A Study Investigators; Fang W, Zhao Y, Luo Y, Yang R, Huang Y, He Z, Zhao H, Li M, Li K, Song Q, Du X, Sun Y, Li W, Xu F, Wang Z, Yang K, Fan Y, Liu B, Zhao H, Hu Y, Jia L, Xu S, Yi T, Lv D, Lan H, Li M, Liang W, Wang Y, Yang H, Jia Y, Chen Y, Lu J, Feng J, Liu C, Zhou M, Zhou J, Liu X, Zhou N, He M, Dong X, Chen H, Chen Y, Su H, Li X, Zhang Z, Yang L, Cheng Y, Chen L, Hou X, Zhang Y, Guo J, Wang Z, Lu H, Wu D, Feng W, Li W, Huang J, Wang Y, Song X, Peng J, Liu L, Guo Y, Li W, Lu D, Hu M, Wang ZM, Li B, Xia M, Zhang L. Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial. JAMA. 2024 Aug 20;332(7):561-570. doi: 10.1001/jama.2024.10613. PubMed 38820549